IGC Pharma Reports Third Quarter 2026 Financial Results and Provides Business Update
IGC Pharma reported Q3 2026 revenue of approximately $328 thousand, up 72% year-over-year, with a net loss attributable to common stockholders of approximately $2.046 million ($0.02 per share). The Phase 2 CALMA trial of IGC-AD1 in Alzheimer's agitation completed enrollment with 170 participants randomized, above the 146 target, and the company is preparing database lock, unblinding, and independent statistical analysis for topline results. IP protection expanded with a Canadian patent granted October 27, bringing issued patents covering IGC-AD1 to five, with ten more applications pending worldwide.
Key figures
- Revenue
- $328 thousand
- Revenue Yoy
- 72%
- Net loss
- $2.046 million
- Rd expense
- $1.0 million
- Sga expense
- $979 thousand
- Granted patents
- 5
- Capital raised 9m
- $4.1 million
- Calma participants
- 170
- Cash and equivalents
- $377 thousand
- Undrawn credit facility
- $12 million
- Pending patent applications
- 10
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.